Tiagabine

Tiagabine

SCHEMBL7346237

Cc1ccsc1C(=CCCN1CCC[C@@H](C(=O)O)C1)c1sccc1C.O

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC6A1

The experimentally established mechanism targets of Tiagabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
SLC6A1 known ✓ P30531 10/20 0.98
PTGS1 P23219 1/20 0.98
PDE4A P27815 1/20 0.98
CYP1A2 P05177 1/20 0.62
CYP2D6 P10635 1/20 0.62
CYP2C9 P11712 1/20 0.62
TSHR P16473 1/20 0.62
NFKB1 P19838 1/20 0.62
CYP2C19 P33261 1/20 0.62
HSD17B10 Q99714 1/20 0.62
ALDH1A1 P00352 1/20 0.62
LMNA P02545 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tiagabine SCHEMBL1527642 0.99 SLC6A1 (0.98) SLC6A1PTGS1PDE4AALDH1A1LMNA
Tiagabine SCHEMBL34653 0.99 SLC6A1 (1.00) SLC6A1PTGS1PDE4ACYP1A2CYP2D6
Tiagabine SCHEMBL342814 0.99 SLC6A1 (1.00) SLC6A1PTGS1PDE4ACYP1A2CYP2D6
Tiagabine SCHEMBL3272861 0.99 SLC6A1 (1.00) SLC6A1PTGS1PDE4ACYP1A2CYP2D6
Tiagabine SCHEMBL3958156 0.98 SLC6A1 (0.98) SLC6A1PTGS1PDE4ACYP1A2CYP2D6
Tiagabine SCHEMBL41860 0.98 SLC6A1 (1.00) SLC6A1PTGS1PDE4AALDH1A1LMNA
Tiagabine SCHEMBL5164417 0.98 SLC6A1 (1.00) SLC6A1PTGS1PDE4AALDH1A1LMNA
Tiagabine SCHEMBL18496408 0.98 SLC6A1 (1.00) SLC6A1PTGS1PDE4AALDH1A1LMNA
Tiagabine SCHEMBL17493682 0.98 SLC6A1 (1.00) SLC6A1PTGS1PDE4AALDH1A1LMNA
Tiagabine SCHEMBL3243472 0.95 SLC6A1 (0.90) SLC6A1PTGS1PDE4AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0579681-B1 CRYSTALLINE TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND USE NOVO NORDISK AS (DK) 1999-06-02 EP disclosed
US-5354760-A Antiepileptic agents; acid-catalyzed hydrolysis of ethyl R-)-N-(4,4-di(3-methylthien-2-yl)but-3-3nyl)nipecotate hydrochloride; crystallization and precipitation from an aqueous solution to form the monohydrate NOVO NORDISK A/S (DK) 1994-10-11 US disclosed
US-5354760-A Antiepileptic agents; acid-catalyzed hydrolysis of ethyl R-)-N-(4,4-di(3-methylthien-2-yl)but-3-3nyl)nipecotate hydrochloride; crystallization and precipitation from an aqueous solution to form the monohydrate NOVO NORDISK A/S (DK) 1994-10-11 US disclosed
EP-0579681-A1 CRYSTALLINE TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND USE NOVO NORDISK A/S (DK) 1994-01-26 EP disclosed
WO-1992017473-A1 CRYSTALLINE TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND USE NOVO NORDISK A/S (DK) 1992-10-15 WO disclosed